ATE412429T1 - Impfstoffzusammensetzung im gemisch mit einem alkylphosphatidylcholin - Google Patents

Impfstoffzusammensetzung im gemisch mit einem alkylphosphatidylcholin

Info

Publication number
ATE412429T1
ATE412429T1 AT04805451T AT04805451T ATE412429T1 AT E412429 T1 ATE412429 T1 AT E412429T1 AT 04805451 T AT04805451 T AT 04805451T AT 04805451 T AT04805451 T AT 04805451T AT E412429 T1 ATE412429 T1 AT E412429T1
Authority
AT
Austria
Prior art keywords
alkylphosphatidylcholine
vaccine composition
composition mixed
pharmaceutical composition
additionally contains
Prior art date
Application number
AT04805451T
Other languages
English (en)
Inventor
Jean Haensler
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Application granted granted Critical
Publication of ATE412429T1 publication Critical patent/ATE412429T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04805451T 2003-11-17 2004-11-15 Impfstoffzusammensetzung im gemisch mit einem alkylphosphatidylcholin ATE412429T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0313406A FR2862306B1 (fr) 2003-11-17 2003-11-17 Composition vaccinale

Publications (1)

Publication Number Publication Date
ATE412429T1 true ATE412429T1 (de) 2008-11-15

Family

ID=34508504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04805451T ATE412429T1 (de) 2003-11-17 2004-11-15 Impfstoffzusammensetzung im gemisch mit einem alkylphosphatidylcholin

Country Status (23)

Country Link
US (2) US7344720B2 (de)
EP (1) EP1696954B1 (de)
JP (1) JP4638880B2 (de)
KR (1) KR101136107B1 (de)
CN (1) CN1882358B (de)
AT (1) ATE412429T1 (de)
AU (1) AU2004290943B2 (de)
BR (1) BRPI0416670A (de)
CA (1) CA2545086C (de)
CY (1) CY1108498T1 (de)
DE (1) DE602004017504D1 (de)
DK (1) DK1696954T3 (de)
ES (1) ES2311875T3 (de)
FR (1) FR2862306B1 (de)
IL (1) IL175573A (de)
LT (1) LT5435B (de)
LV (1) LV13457B (de)
NO (1) NO20062779L (de)
PL (1) PL1696954T3 (de)
PT (1) PT1696954E (de)
SI (1) SI1696954T1 (de)
WO (1) WO2005049080A1 (de)
ZA (1) ZA200603522B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100752990B1 (ko) * 2006-08-02 2007-08-30 주식회사 대웅 나노리포좀 및 천연 추출물을 포함하는 피부 질환의 예방또는 치료용 조성물
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
MX2010008799A (es) 2008-03-05 2010-09-07 Sanofi Pasteur Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
EP2429659B1 (de) * 2009-05-14 2017-12-13 Sanofi Pasteur Verfahren zur entgiftung des lipopolysaccharids (lps) oder von lipid a von gram-negativen bakterien
CA2761924C (fr) 2009-05-14 2017-10-31 Sanofi Pasteur Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6
AU2010247252A1 (en) 2009-05-14 2012-01-12 Sanofi Pasteur Method for admixing the lipopolysaccharide (LPS) of gram-negative bacteria
EP2578974A1 (de) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Verfahrenslinie zur Herstellung von gefriergetrockneten Partikeln
JP5761143B2 (ja) * 2011-11-02 2015-08-12 株式会社リコー 撮像ユニット、撮像ユニットを搭載した車両
US20140147475A1 (en) * 2012-11-29 2014-05-29 Antonius Arnoldus Christiaan Jacobs Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida
HUE048344T2 (hu) 2013-03-18 2020-08-28 Intervet Int Bv Vakcina kérõdzõ védelmére Mannheimia haemolytica okozta tüdõgyulladás ellen
US10533800B2 (en) 2014-07-21 2020-01-14 Sanofi Pasteur Sa Liquid feeding device for the generation of droplets

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
SG137691A1 (en) * 2000-09-28 2007-12-28 Chiron Corp Microparticles for delivery of the heterologous nucleic acids
AU1486102A (en) * 2000-11-07 2002-05-21 Immunovaccine Technologies Inc Vaccines with enhanced immune response and methods for their preparation
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use

Also Published As

Publication number Publication date
DK1696954T3 (da) 2009-02-23
CY1108498T1 (el) 2014-04-09
EP1696954B1 (de) 2008-10-29
IL175573A0 (en) 2006-09-05
ZA200603522B (en) 2007-07-25
BRPI0416670A (pt) 2007-02-13
LT5435B (lt) 2007-07-25
DE602004017504D1 (de) 2008-12-11
ES2311875T3 (es) 2009-02-16
AU2004290943A1 (en) 2005-06-02
KR101136107B1 (ko) 2012-04-17
CN1882358B (zh) 2011-02-02
NO20062779L (no) 2006-08-15
US7344720B2 (en) 2008-03-18
KR20060127385A (ko) 2006-12-12
WO2005049080B1 (fr) 2005-09-01
CA2545086A1 (en) 2005-06-02
SI1696954T1 (sl) 2009-04-30
LT2006036A (en) 2007-05-25
PT1696954E (pt) 2008-11-25
EP1696954A1 (de) 2006-09-06
FR2862306A1 (fr) 2005-05-20
US7767658B2 (en) 2010-08-03
JP2007511585A (ja) 2007-05-10
US20050208060A1 (en) 2005-09-22
AU2004290943B2 (en) 2009-08-27
FR2862306B1 (fr) 2008-05-30
JP4638880B2 (ja) 2011-02-23
CA2545086C (en) 2011-11-08
WO2005049080A1 (fr) 2005-06-02
LV13457B (en) 2007-01-20
PL1696954T3 (pl) 2009-04-30
US20080131446A1 (en) 2008-06-05
CN1882358A (zh) 2006-12-20
IL175573A (en) 2010-06-30

Similar Documents

Publication Publication Date Title
NO20062779L (no) Vaksinesammensetning blandet med en alkylfosfatidylkolin
CY1108823T1 (el) Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
CY1108295T1 (el) Παραγωγα μονοσακχαριτη αβερμεκτινης τα οποια εχουν παρασιτοκτονες ιδιοτητες
EA200501098A1 (ru) Антибактериальные агенты
CL2004000969A1 (es) Compuestos derivados de alquilarilo; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de la obesidad y trastornos relacionados.
BRPI0507801A (pt) compostos de azetidina substituìda, processo para a preparação de compostos de azetidina substituìda, medicamento e uso de pelo menos um composto de azetidina substituìda
BRPI0617918B8 (pt) compostos de fórmula (i) e seu uso, medicamentos e composição farmacêutica
BR0316690A (pt) Composto, prodroga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
DE69229442D1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
BRPI0406824A (pt) Indolonaoxazoldinonas antiibacterianas, intermediários para seu preparo e composições farmacêuticas que as contêm
ATE486852T1 (de) Salze von 9-oxoacridin-10-essigsäure mit 1- alkylamino-1-desoxypolyolen
AR029795A1 (es) Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos
ES8502126A1 (es) Un procedimiento para la preparacion de derivados de milbenicina d
BR0311810A (pt) Preparação revestida, processo para a produção e uso da mesma, processo para a produção de pelo menos uma ração e/ou aditivo para rações contendo pelo menos um diformiato, e, ração para animais
BR0312385A (pt) Preparação, processos para produzir a mesma e uma ração contendo diformiato e/ou aditivo de ração, uso de uma preparação, e, ração animal
ES2079349T3 (es) Sales por adicion de acidos de cefem cristalizadas y procedimiento para su preparacion.
ITMI911853A1 (it) Sale del diclofenac, metodo di preparazione e composizioni farmaceutiche che lo contengono.
EE200200599A (et) Tsüklipostiiniühend kasutamiseks diabeedivastase ravimina, seda sisaldav farmatseutiline preparaat,ühendi ja preparaadi valmistamine ning selleks vajalik mikroorganism
PT1123937E (pt) Substancia gm-95 processo para a sua preparacao e a sua utilizacao
EA200000374A2 (ru) Новые соединения 2,3-метаноаминокислоты, способ их получения и содержащие их фармацевтические композиции
BR0213633A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ou ativação aberrante de leucócitos
AR031712A1 (es) Metodo y composicion
KR890005119A (ko) 마크롤리드 화합물
ES8506009A1 (es) Un procedimiento para la preparacion de derivados de oxacefalosporina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1696954

Country of ref document: EP